186 related articles for article (PubMed ID: 21633805)
1. Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy.
Geisberg CA; Lenihan DJ
Herz; 2011 Jun; 36(4):306-10. PubMed ID: 21633805
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxic effects of trastuzumab.
Hysing J; Wist E
Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2239-41. PubMed ID: 22085949
[TBL] [Abstract][Full Text] [Related]
3. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 inhibition and heart failure.
Cote GM; Sawyer DB; Chabner BA
N Engl J Med; 2012 Nov; 367(22):2150-3. PubMed ID: 23190227
[No Abstract] [Full Text] [Related]
6. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
De Keulenaer GW; Doggen K; Lemmens K
Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
8. Neuregulin-1 and its potential role in the control of cardiac function.
Lemmens K; Doggen K; Keulenaer GW
Heart Fail Monit; 2008 Feb; 5(4):119-24. PubMed ID: 18273495
[TBL] [Abstract][Full Text] [Related]
9. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.
Hedhli N; Russell KS
Curr Hypertens Rep; 2010 Dec; 12(6):411-7. PubMed ID: 20878505
[TBL] [Abstract][Full Text] [Related]
10. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
11. Neuregulin-1/ErbB signaling and chronic heart failure.
Xu Y; Li X; Liu X; Zhou M
Adv Pharmacol; 2010; 59():31-51. PubMed ID: 20933198
[TBL] [Abstract][Full Text] [Related]
12. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure.
Lemmens K; Doggen K; De Keulenaer GW
Circulation; 2007 Aug; 116(8):954-60. PubMed ID: 17709650
[TBL] [Abstract][Full Text] [Related]
13. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure.
Lenneman CG
Curr Heart Fail Rep; 2014 Jun; 11(2):134-8. PubMed ID: 24682830
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
15. Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab.
Barth AS; Zhang Y; Li T; Smith RR; Chimenti I; Terrovitis I; Davis DR; Kizana E; Ho AS; O'Rourke B; Wolff AC; Gerstenblith G; Marbán E
Stem Cells Transl Med; 2012 Apr; 1(4):289-97. PubMed ID: 23197808
[TBL] [Abstract][Full Text] [Related]
16. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
Lemieux J; Diorio C; Côté MA; Provencher L; Barabé F; Jacob S; St-Pierre C; Demers E; Tremblay-Lemay R; Nadeau-Larochelle C; Michaud A; Laflamme C
Anticancer Res; 2013 Jun; 33(6):2569-76. PubMed ID: 23749910
[TBL] [Abstract][Full Text] [Related]
17. Anticancer therapy induced cardiotoxicity: review of the literature.
Geiger S; Lange V; Suhl P; Heinemann V; Stemmler HJ
Anticancer Drugs; 2010 Jul; 21(6):578-90. PubMed ID: 20375725
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin signaling and heart failure.
Jiang Z; Zhou M
Curr Heart Fail Rep; 2010 Mar; 7(1):42-7. PubMed ID: 20425496
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
Suter TM; Cook-Bruns N; Barton C
Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
[TBL] [Abstract][Full Text] [Related]
20. Central neuregulin-1/ErbB signaling modulates cardiac function via sympathetic activity in pressure overload-induced heart failure.
Matsukawa R; Hirooka Y; Ito K; Honda N; Sunagawa K
J Hypertens; 2014 Apr; 32(4):817-25. PubMed ID: 24406781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
